SBP-101

Panbela Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	SBP-101
Also known as	diethyl dihydroxyhomospermine, [(HO)2-DEHSPM], ivospemin
Sponsor	Panbela Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (PHASE2, PHASE3)
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer (PHASE1)
Study of SBP-101 in Pancreatic Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SBP-101 CI brief — competitive landscape report
SBP-101 updates RSS · CI watch RSS
Panbela Therapeutics, Inc. portfolio CI